---
title: "Lirum Therapeutics, Inc. (LRTX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/LRTX.US.md"
symbol: "LRTX.US"
name: "Lirum Therapeutics, Inc."
industry: "Biotechnology"
---

# Lirum Therapeutics, Inc. (LRTX.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |

## Company Profile

Lirum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the treatment of debilitating diseases. Its lead product candidate is LX-101, an insulin-like growth factor-1 receptor directed agent to treat patients with various cancers and autoimmune diseases, including thyroid eye...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/LRTX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/LRTX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/LRTX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.